Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 9:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 31 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: TSPO PET Clear all
Not listed No phase listed Observational

Longitudinal Tracking of Patients Diagnosed With Neurodegenerative Movement Disorders

NCT05486806
View directory record Official record
Conditions
Neurodegenerative Diseases, sca3, MSA - Multiple System Atrophy, Ataxia, Synucleinopathies
Interventions
18F-PBR06, 18F-PBR06
Drug · Radiation
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
50 participants
Timeline
2023 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 22, 2023 · Synced Oct 18, 2026, 9:05 AM EDT
Completed No phase listed Observational

Long-Term Effects of Repetitive, Low-Level Blast Exposure on Special Operations Forces Service Members

NCT05183087
View directory record Official record
Conditions
Traumatic Brain Injury, Blast Injuries
Interventions
3T Connectome MRI, 7 Tesla MRI, TSPO PET, Tau PET, Cognitive and Behavioral Assessments, Blood Biomarkers
Diagnostic Test
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
25 Years to 45 Years · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 4, 2023 · Synced Oct 18, 2026, 9:05 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Comparison of Microglial Activation in Severe Asthma and Healthy Controls

NCT06299592
View directory record Official record
Conditions
Asthma
Interventions
PET/MRI using [18F]FEPPA tracer
Combination Product
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 18, 2026, 9:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Neuroimmune Effects of Opioid Administration

NCT03801629
View directory record Official record
Conditions
Drug Effect
Interventions
High Morphine Dose, Low Morphine Dose
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 50 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 27, 2021 · Synced Oct 18, 2026, 9:05 AM EDT
Not listed Phase 2 Interventional

Systemic and Central Inflammation in AD

NCT06384378
View directory record Official record
Conditions
Alzheimer Disease
Interventions
11C-ER176
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
50 Years to 86 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 25, 2024 · Synced Oct 18, 2026, 9:05 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

PET Imaging of Neuroinflammation in Neurodegenerative Diseases Via a Novel Translocator Protein (TSPO) Radioligand

NCT03958630
View directory record Official record
Conditions
Dementia
Interventions
11C-ER176, 11C-PIB, Positron Emission Tomography (PET) Scan
Drug · Diagnostic Test
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 1, 2024 · Synced Oct 18, 2026, 9:05 AM EDT
Active, not recruiting Phase 1 Interventional

Imaging of Neuro-Inflammation and the Risk for Post-Traumatic Epilepsy

NCT03999164
View directory record Official record
Conditions
Epilepsy, Post-Traumatic
Interventions
[18F]DPA-714 Positron Emission Tomography Scan
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 100 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 18, 2026, 9:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Specific PET Radioligand Binding to Translocator Protein

NCT02181582
View directory record Official record
Conditions
Baseline, Blocking Receptor Binding
Interventions
Emapunil, PET
Drug · Device
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 27, 2018 · Synced Oct 18, 2026, 9:05 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Selective PET Imaging of Astrocytes and Microglia in Alzheimer's Disease

NCT05582200
View directory record Official record
Conditions
Alzheimer Disease, Healthy
Interventions
Positron Emission Tomography (PET) using 11C-ER176 for TSPO and 18F-SMBT1 for MAO-B
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years to 90 Years
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 18, 2026, 9:05 AM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

SV2A & TSPO PET Imaging Measures to Reveal Mechanisms of HIV Neuropathogenesis During Antiretroviral Therapy

NCT05586581
View directory record Official record
Conditions
HIV Associated Neurocognitive Disorder, HIV Dementia, HIV Encephalitis, Healthy
Interventions
SV2A PET, TSPO PET
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 80 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2030
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 18, 2026, 9:05 AM EDT
Active, not recruiting Phase 2 Interventional

Quantitative Assessment of Radiation-induced Neuroinflammation - A Proof of Principle Study

NCT05128903
View directory record Official record
Conditions
Brain Tumor, Medulloblastoma
Interventions
[18F]DPA714
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
8 Years to 39 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2035
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 18, 2026, 9:05 AM EDT
Recruiting Phase 1 Interventional

Molecular Imaging Probes to Inform Heterogeneity in Idiopathic Pulmonary Fibrosis

NCT04362644
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
PET/CT using PET ligands [F-18]FDG and [F-18]DPA-714
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
40 Years to 85 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 18, 2026, 9:05 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Accelerated Non-Atherosclerotic Brain Arterial Aging Relationship to Alzheimer's Disease

NCT04510168
View directory record Official record
Conditions
Alzheimer Disease, Dementia
Interventions
11C-ER176, [F-18]MK-6240, Florbetaben, Magnetic Resonance Imaging
Drug · Other
Lead sponsor
Jose Gutierrez, MD, MPH
Other
Eligibility
50 Years and older
Enrollment
238 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 16, 2024 · Synced Oct 18, 2026, 9:05 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Assessment of [11C]ER176 to Image Translocator Protein in Brain and Whole Body of Healthy People

NCT02147392
View directory record Official record
Conditions
Pharmacokinetics, Adult
Interventions
[11C]ER-176
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 5, 2018 · Synced Oct 18, 2026, 9:05 AM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

The University of Alabama at Birmingham (UAB) Neuroinflammation in Parkinson's Disease-TSPO- Positron Emission Tomography (PET) Substudy

NCT03457493
View directory record Official record
Conditions
Parkinson Disease
Interventions
DPA-714-PET/MRI, 5-year Follow-up DPA-714-PET/MRI, DPA-714 Metabolite Analysis
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
30 Years and older
Enrollment
205 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2028
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 18, 2026, 9:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Neuroimmune Response to Lipopolysaccharide

NCT04233593
View directory record Official record
Conditions
Healthy
Interventions
Lipopolysaccharide
Biological
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2021
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 19, 2022 · Synced Oct 18, 2026, 9:05 AM EDT
Terminated Phase 1 Interventional Results available

Novel PET Radioligand as an Inflammatory Biomarker in Musculoskeletal Conditions

NCT03912428
View directory record Official record
Conditions
Myositis, Inflammatory, Rheumatoid Arthritis, Healthy Volunteers
Interventions
11C-MC1, Celecoxib, [11C]ER176, Positron Emission Tomography (PET)/computed tomography (CT) Scan
Drug · Diagnostic Test
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 99 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Oct 18, 2026, 9:05 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Translocator Protein and Inflammation After Traumatic Brain Injury

NCT01547780
View directory record Official record
Conditions
Traumatic Brain Injury (TBI), Healthy
Interventions
[11C]PBR28 and Positron Emission Tomography (PET)
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 70 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 30, 2021 · Synced Oct 18, 2026, 9:05 AM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Longitudinal TSPO PET Imaging With [18F]DPA-714 in PPMI (PPMI DPA-714 PET Imaging)

NCT06289582
View directory record Official record
Conditions
Parkinson Disease
Interventions
[F-18]DPA714 administration IV
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 99 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 18, 2026, 9:05 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

CNS Correlates of Extended Sleep Restriction

NCT05547880
View directory record Official record
Conditions
Sleep Restriction
Interventions
[11C]ER176
Drug
Lead sponsor
Walter Reed Army Institute of Research (WRAIR)
Federal
Eligibility
18 Years to 39 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated May 18, 2025 · Synced Oct 18, 2026, 9:05 AM EDT
Terminated No phase listed Observational

Methionine and PBR28-PET (Peripheral Benzodiazepine Receptors) in Brain Metastases Following Radiosurgery

NCT02433171
View directory record Official record
Conditions
Brain Metastasis
Interventions
Standard of Care FDG-PET Imaging
Procedure
Lead sponsor
Yale University
Other
Eligibility
18 Years to 80 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 28, 2019 · Synced Oct 18, 2026, 9:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

ONO-2952 Single-dose PET Study in Healthy Adult Subjects

NCT01613703
View directory record Official record
Conditions
Healthy Adult Subjects
Interventions
ONO-2952
Drug
Lead sponsor
Ono Pharma USA Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2012
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 3, 2013 · Synced Oct 18, 2026, 9:05 AM EDT
Terminated Phase 2 Interventional Results available

Study of Safety and Proof of the Mechanism of BLZ945 in ALS Patients

NCT04066244
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
BLZ945
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
2
States / cities
New Haven, Connecticut • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 16, 2025 · Synced Oct 18, 2026, 9:05 AM EDT
Active, not recruiting No phase listed Observational

Neuropsychiatric Post-Acute Sequelae of SARS-CoV-2 (PASC) Using TSPO Positron Emission Tomography (PET) and MRI

NCT05615415
View directory record Official record
Conditions
Neuropsychiatric Post-Acute Sequelae of SARS-CoV-2 Infection
Interventions
PET Tracer, MRI Tracer, 3T PET/MRI
Drug · Device
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Timeline
2022 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 18, 2026, 9:05 AM EDT